Posttreatment SPECT/CT as a Prognostic Tool in Patients Treated with (177)Lu-PSMA-617. Demirci RA, Menda Y. Radiol Imaging Cancer 2025;7:e259020.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Demirci RA, Menda Y. Posttreatment SPECT/CT as a Prognostic Tool in Patients Treated with (177)Lu-PSMA-617. Radiol Imaging Cancer 2025;7:e259020.
PMID: 40970795